Recent News

• 04.27.2025 - UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
• 04.27.2025 - UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
• 04.24.2025 - Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data
• 04.14.2025 - UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
• 04.14.2025 - UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
• 04.14.2025 - Relmada Therapeutics To Present NDV-01 Data at AUA2025
• 03.27.2025 - Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
• 03.27.2025 - Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
• 03.26.2025 - Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025
• 03.25.2025 - Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Recent Filings

• 04.11.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.11.2025 - DEF 14A Other definitive proxy statements
• 03.27.2025 - EX-99.1 EX-99.1
• 03.27.2025 - 8-K Current report
• 03.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.26.2025 - EX-99.1 EX-99.1
• 03.26.2025 - 8-K Current report
• 02.06.2025 - EX-99.1 EX-99.1